Novel treatment of non-small cell lung cancer with the inhibition of IL-26-induced tumor angiogenesis
Project/Area Number |
17590775
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Respiratory organ internal medicine
|
Research Institution | TOHOKU UNIVERSITY |
Principal Investigator |
NUMASAKI Muneo TOHOKU UNIVERSITY, Tohoku University Hospital, Research Associate (50344677)
|
Co-Investigator(Kenkyū-buntansha) |
SUZUKI Takashi TOHOKU UNIVERSITY, Faculty of Medicine, Professor (10261629)
|
Project Period (FY) |
2005 – 2006
|
Project Status |
Completed (Fiscal Year 2006)
|
Budget Amount *help |
¥3,600,000 (Direct Cost: ¥3,600,000)
Fiscal Year 2006: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 2005: ¥2,600,000 (Direct Cost: ¥2,600,000)
|
Keywords | angiogenesis / cytokine / non-small cell lung cancer / 肺癌 |
Research Abstract |
In this study, we examined the biological action of IL-26 on human non-small cell lung cancer (NSCLC). While IL-26 had no direct effect on the in vitro growth rate of NSCLC, IL-26 selectively augmented the secretion of an array of angiogenic CXC chemokines including CXCL1, CXCL5, CXCL6 and CXCL8, but not angiostatic chemokines, by two different NSCLC lines. Transfection with IL-26 into NSCLC had no effect on the in vitro growth, whereas IL-26 transfectants grew more rapidly compared with controls when transplanted in SCID mice. This IL-26-elicited enhanced NSCLC growth was associated with increased tumor vascularity. Moreover, treatment with anti-mouse CXCR-2 neutralizing Ab significantly attenuated the growth of both Neo- and IL-26-transfected NSCLC tumors in SCID mice. These results demonstrate that IL-26 increases the net angiogenic activity and in vivo growth of NSCLC via promoting CXCR-2-dependent angiogenesis and suggest that targeting CXCR-2 signaling may be a novel promising strategy to treat patients with NSCLC.
|
Report
(3 results)
Research Products
(7 results)